AbbVie (ABBV)
(Delayed Data from NYSE)
$159.62 USD
-7.67 (-4.58%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $160.06 +0.44 (0.28%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Income Statements
Fiscal Year end for AbbVie Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 54,318 | 58,054 | 56,197 | 45,804 | 33,266 |
Cost Of Goods | 20,415 | 17,414 | 17,446 | 15,387 | 7,439 |
Gross Profit | 33,903 | 40,640 | 38,751 | 30,417 | 25,827 |
Selling & Adminstrative & Depr. & Amort Expenses | 21,146 | 22,523 | 20,827 | 19,054 | 12,844 |
Income After Depreciation & Amortization | 12,757 | 18,117 | 17,924 | 11,363 | 12,983 |
Non-Operating Income | -4,823 | -2,596 | -2,551 | -5,685 | -3,048 |
Interest Expense | 1,684 | 2,044 | 2,384 | 2,280 | 1,509 |
Pretax Income | 6,250 | 13,477 | 12,989 | 3,398 | 8,426 |
Income Taxes | 1,377 | 1,632 | 1,440 | -1,224 | 544 |
Minority Interest | 10 | 9 | 7 | 6 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 4,873 | 11,845 | 11,549 | 4,622 | 7,882 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 4,863 | 11,836 | 11,542 | 4,616 | 7,882 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 21,455 | 26,584 | 26,445 | 17,834 | 15,000 |
Depreciation & Amortization (Cash Flow) | 8,698 | 8,467 | 8,521 | 6,471 | 2,017 |
Income After Depreciation & Amortization | 12,757 | 18,117 | 17,924 | 11,363 | 12,983 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1,773.00 | 1,778.00 | 1,777.00 | 1,673.00 | 1,484.00 |
Diluted EPS Before Non-Recurring Items | 11.11 | 13.77 | 12.70 | 10.56 | 8.94 |
Diluted Net EPS (GAAP) | 2.72 | 6.63 | 6.45 | 2.72 | 5.28 |
Fiscal Year end for AbbVie Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 14,301.00 | 13,927.00 | 13,865.00 | 12,225.00 |
Cost Of Goods | NA | 5,704.00 | 6,485.00 | 4,240.00 | 3,986.00 |
Gross Profit | NA | 8,597.00 | 7,442.00 | 9,625.00 | 8,239.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5,402.00 | 5,161.00 | 5,112.00 | 5,471.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3,195.00 | 2,281.00 | 4,513.00 | 2,768.00 |
Non-Operating Income | NA | -1,605.00 | 70.00 | -1,449.00 | -1,839.00 |
Interest Expense | NA | 378.00 | 398.00 | 454.00 | 454.00 |
Pretax Income | NA | 1,212.00 | 1,953.00 | 2,610.00 | 475.00 |
Income Taxes | NA | 388.00 | 172.00 | 583.00 | 234.00 |
Minority Interest | NA | 2.00 | 3.00 | 3.00 | 2.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 824.00 | 1,781.00 | 2,027.00 | 241.00 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 822.00 | 1,778.00 | 2,024.00 | 239.00 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 1,772.00 | 1,771.00 | 1,771.00 | 1,776.00 |
Diluted EPS Before Non-Recurring Items | NA | 2.79 | 2.95 | 2.91 | 2.46 |
Diluted Net EPS (GAAP) | NA | 0.45 | 1.00 | 1.14 | 0.13 |